您好,欢迎光临世界标品! 登录 注册(订药物标准品请用邮件联系我们)

SCITEK INTERNATIONAL (H.K.) LIMITED
Email: sciteck.hongkong@gmail.com
 

当前本网站药物产品种数共 8524 处方药 8148 非处方药 269 保健品/医疗用具 107

世界标品医药目录搜索(中英文):
世界各国官方药品目录搜索(英文):
世界标品医药知识搜索(中英文):

联系方式
国内客服电话:
国际免费电话:

咨询邮箱:
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com

  药店国别: 美国药房
产地国家: 美国
所属类别: 抗癌药物->治疗乳腺癌药物
处方药:处方药
包装规格: 160毫克/支
计价单位:
   
生产厂家英文名:
GENENTECH
该药品相关信息网址1:
http://www.kadcyla.com/?cid=kad_PS_MBKDBC0001&c=MBKDUA1001&moc=MBKDUA1001&gclid=CMGLqMSBgrwCFeZ7QgodLyQA5A
原产地英文商品名:
KADCYLA 160MG/vial
原产地英文药品名:
ADO﹣TRASTUZUMAB EMTANSINE
中文参考商品译名:
贺癌宁 160毫克/支
中文参考药品译名:
曲妥珠单抗注射液
原产地国家批准上市年份:
0000/00/00
英文适应病症1:
HER2-positive breast cancer
临床试验期:
完成
中文适应病症参考翻译1:
HER2-阳性乳腺癌
药品信息:

---------------------------------------------------------------
详细处方信息以本药内容附件PDF文件(201411522214319.pdf)的“原文Priscribing Information”为准

适应证和用途

KADCYLA是一种靶向HER2抗体和微管抑制剂结合物适用于,作为单药,为有HER2-阳性,转移乳癌,既往接受曲妥珠单抗和一种紫衫烷类,分开或联合应用患者的治疗。患者应有以下任一情况:

(1)对转移疾病以前接受治疗,或

(2)完成辅助治疗期间或6个月内疾病复发。(1)

剂量和给药方法

(1)只为静脉输注。不要静推注或丸注。不要使用葡萄糖(5%)溶液。 (2.3)

(2)KADCYLA的推荐剂量是3.6 mg/kg每3周(21-天周期)静脉输注给药直至疾病进展或不能接受毒性。不要给予剂量大于3.6 mg/kg的KADCYLA。不要替代KADCYLA或用曲妥珠单抗。(2.1)

(3)不良事件的处理(输注相关反应,肝毒性,左心室功能障碍,血小板减少,肺毒性或周围神经病变)可能需要暂时中断,减低剂量,或终止KADCYLA治疗。(2.2)

剂型和规格

在单次使用小瓶冻干粉含100 mg每小瓶或160 mg每小瓶. (3)

禁忌证

无。(4)

警告和注意事项

(1)肺毒性:在被诊断有间质性肺病或肺炎患者中永久终止KADCYLA。(2.2,5.4)

(2)输注相关反应,超敏性反应:输注期间和后监视体征和症状。如发生重要输注相关反应或超敏性反应,减慢或中断输注和给予适当医学治疗。对危及生命输注相关反应永久终止KADCYLA。(2.1,2.2,5.5)

(3)血小板减少:每次给予KADCYLA前监视血小板计数。适当时调整剂量。(2.2,5.6)

(4)神经毒性:监视体征和症状。对经受3或4级周围神经病变患者暂时不用给药。(2.2,5.7,13.2)

(5)HER2检验:由有测试能力的实验室用FDA-批准的检验进行检验。(5.8)

不良反应

用KADCYLA (n=884被治疗患者)最常见不良反应(频数> 25%)是疲乏,恶心,肌肉骨骼痛,血小板减少,头痛,转氨酶增加,和便秘。(6.1) 为报告怀疑不良反应,联系Genentech电话1-888-835-2555或FDA电话1-800-FDA-1088或www.fda.gov/medwatch.

在特殊人群中使用

(1)哺乳母亲:终止哺乳或终止KADCYLA考虑到药物对母亲的重要性。(8.3)

(2)生殖潜能妇女:忠告女性关于预防和计划妊娠。鼓励患者参加母亲妊娠注册通过联系1-800-690-6720)。(5.3,8.1,8.6)

Who is KADCYLA for?

KADCYLA® is approved to treat HER2-positive breast cancer that has spread to other parts of the body (metastatic breast cancer) after prior treatment with trastuzumab (Herceptin®) and a taxane. Prior treatment could have been for the initial treatment of breast cancer or for the treatment of cancer that had spread to other parts of the body.

Important Safety Information

What is the most important safety information I should know about KADCYLA?

KADCYLA is not the same medicine as trastuzumab (Herceptin).

Liver problems

KADCYLA may cause severe liver problems that can be life-threatening.

Symptoms of liver problems may include vomiting, nausea, eating disorder (anorexia), yellowing of the skin (jaundice), stomach pain, dark urine, or itching

Heart problems

KADCYLA may cause heart problems, including those without symptoms (such as reduced heart function) and those with symptoms (such as congestive heart failure). Symptoms may include swelling of the ankles or legs, shortness of breath, cough, rapid weight gain of greater than 5 lbs in less than 24 hours, dizziness or loss of consciousness, or irregular heart beat

Pregnancy

Receiving KADCYLA during pregnancy can result in the death of an unborn baby and birth defects. Birth control should be used while you receive KADCYLA and for 6 months after your last dose of KADCYLA

If you are exposed to KADCYLA during pregnancy, contact your healthcare provider right away; you are also encouraged to enroll in the MotHER Pregnancy Registry by calling 1 (800) 690-6720

If you are a mother who is breastfeeding, you should talk with your doctor about either stopping breastfeeding or stopping KADCYLA

Contact your doctor right away if you experience symptoms associated with these side effects.

What are the additional possible serious side effects of KADCYLA?

Lung problems

KADCYLA may cause lung problems, including inflammation of the lung tissue, which can be life-threatening. Signs of lung problems may include trouble breathing, cough, tiredness, and fluid in the lungs Infusion-related reactions

Symptoms of an infusion-related reaction may include one or more of the following: the skin getting hot or red (flushing), chills, fever, trouble breathing, low blood pressure, wheezing, tightening of the muscles in the chest around the airways, or a fast heartbeat. Your doctor will monitor you for infusion-related reactions

Low platelet count

Low platelet count may happen during treatment with KADCYLA. Platelets help your blood to clot. Signs of low platelets may include easy bruising, bleeding, and prolonged bleeding from cuts. In mild cases there may not be any symptoms Nerve damage

Symptoms may include numbness and tingling, burning or sharp pain, sensitivity to touch, lack of coordination, muscle weakness, or loss of muscle function

Skin reactions around the infusion site

KADCYLA may leak from the vein or needle and cause reactions such as redness, tenderness, skin irritation, or pain or swelling at the infusion site. If this happens, it is more likely to happen within 24 hours of the infusion

How will my doctor know if KADCYLA is right for me?

You must have a HER2 test to determine if your cancer is HER2-positive before taking KADCYLA, because benefit has been shown only in patients whose tumors are HER2-positive.

What are the most common side effects of KADCYLA?

The most common side effects seen in people taking

KADCYLA are:

Tiredness

Nausea

Pain that affects the bones, muscles, ligaments, and tendons

Low platelet count

Headache

Liver problems

Constipation

更新日期: 2013-07-30
附件:
 
调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间:太平洋时间18:00-24:00
国内客服电话:     国际免费电话:
友情提示:以上电话为免费电话,无需您承担任何费用,世界标品提供中文客服,请您放心拨打!
电子邮箱:sciteck.hongkong@gmail.com, 15901965168@163.com